{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:04:04Z","timestamp":1790147044135,"version":"4.0.1"},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"7","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>One of the primary causes of severe vision loss globally is age-related macular\ndegeneration (AMD), and the mainstay of therapies for neovascular diseases is intravenous administration\nof anti-VEGF (vascular endothelial growth factor) drugs. The goal of this research is to\ncreate an effective delivery of anti-VEGF drugs to overcome the challenges associated with current\ntherapy and adverse effects arising from repetitive intravitreal injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Pazopanib (PZ) nanoparticles (NPs) have been generated to deliver the anti-VEGF drug to\nthe posterior segment of the eye over an extended period via intravitreal injection. They were subsequently\ninvestigated for physicochemical and in vitro studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The PZ NPs were found to be nano-sized with a particle size of 132.1 \u00b1 1.4 nm and a PDI of\n0.125 \u00b1 0.023. The results showed that the zeta potential was -20.12 \u00b1 2.7 mV and the entrapment\nefficiency was 33.9 \u00b1 2.5%. Up to seven days of controlled drug release was observed in an in vitro\ndrug release study. The PZ NPs were further assessed for cell cytotoxicity, cellular uptake, and anti-\nVEGF assays in in vitro cell culture investigations employing human retinal pigment epithelium cells\n(ARPE-19). In vitro cell culture tests revealed that, in comparison to the drug solution, the PZ NPs\nformulation was well taken up by the cells and less cytotoxic, as well as exhibited greater antiangiogenic\nefficacy by inhibiting VEGF expression for an extended period of time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>The NPs demonstrated sustained drug release, driven by their controlled degradation\nkinetics. Increased potential intensity enhanced electrostatic repulsion, thereby improving NP stability.\nThe low entrapment efficiency of PZ in the NPs was likely due to drug diffusion during emulsification\nand poor compatibility with the hydrophilic polymer matrix. For in vitro studies, ARPE-19\ncells were selected due to their retinal pigment epithelial (RPE)-like properties, making them suitable\nfor AMD drug testing. Efficacy (ELISA) assessments revealed that NP formulations had a stronger\ninhibitory effect than free drug solutions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The proposed PZ NPs were successfully developed, characterized, and demonstrated\npotential application in the treatment of AMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672018385478251124140833","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T11:11:21Z","timestamp":1767957081000},"page":"791-802","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Formulation Development and In vitro Characterization of Nanoparticles of Pazopanib for Wet Macular Degeneration"],"prefix":"10.2174","volume":"23","author":[{"given":"Gulimirerouzi","family":"Fnu","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Wegmans School of Pharmacy, St. John Fisher University, Rochester,NY 14618, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba Varghese","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-2298","authenticated-orcid":true,"given":"Vijaykumar","family":"Sutariya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","volume":"3","author":"Pennington K.L.","year":"2016","unstructured":"Pennington K.L.; DeAngelis M.M.; Epidemiology of age-related macular degeneration (AMD): Associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond)  2016,3(1),34","journal-title":"Eye Vis (Lond)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","volume":"105","author":"Thomas C.J.","year":"2021","unstructured":"Thomas C.J.; Mirza R.G.; Gill M.K.; Age-related macular degeneration. Med Clin North Am  2021,105(3),473-491","journal-title":"Med Clin North Am"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(22)02609-5","volume":"401","author":"Guymer R.H.","year":"2023","unstructured":"Guymer R.H.; Campbell T.G.; Age-related macular degeneration. Lancet  2023,401(10386),1459-1472","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000517520","volume":"244","author":"Flores R.","year":"2021","unstructured":"Flores R.; Carneiro \u00c2.; Vieira M.; Tenreiro S.; Seabra M.C.; Age-related macular degeneration: Pathophysiology, management and future perspectives. Ophthalmologica  2021,244(6),495-511","journal-title":"Ophthalmologica"},{"key":"ref=5","first-page":"527","volume":"6","author":"Cheung G.C.M.","year":"2017","unstructured":"Cheung G.C.M.; Lai T.Y.Y.; Gomi F.; Ruamviboonsuk P.; Koh A.; Lee W.K.; Anti-VEGF therapy for neovascular amd and polypoidal choroidal vasculopathy. Asia Pac J Ophthalmol (Phila)  2017,6(6),527-534","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0974-9233.154388","volume":"22","author":"Frank R.","year":"2015","unstructured":"Frank R.; Diabetic retinopathy and systemic factors. Middle East Afr J Ophthalmol  2015,22(2),151-156","journal-title":"Middle East Afr J Ophthalmol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e49211","DOI":"10.7759\/cureus.49211","volume":"15","author":"Chaurasia S.","year":"2023","unstructured":"Chaurasia S.; Thool A.R.; Ansari K.K.; Saifi A.I.; Advancement in understanding diabetic retinopathy: A Comprehensive review. Cureus  2023,15(11),e49211","journal-title":"Cureus"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2913612","volume":"2016","author":"Al Gwairi O.","year":"2016","unstructured":"Al Gwairi O.; Thach L.; Zheng W.; Osman N.; Little P.J.; Cellular and molecular pathology of age-related macular degeneration: Potential role for proteoglycans. J Ophthalmol  2016,2016,1-7","journal-title":"J Ophthalmol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/14740338.2021.1952979","volume":"21","author":"Ng D.S.C.","year":"2022","unstructured":"Ng D.S.C.; Ho M.; Iu L.P.L.; Lai T.Y.Y.; Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. Expert Opin Drug Saf  2022,21(1),43-54","journal-title":"Expert Opin Drug Saf"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CIA.S143508","volume":"12","author":"Al-Zamil W.","year":"2017","unstructured":"Al-Zamil W.; Yassin S.; Recent developments in age-related macular degeneration: A review. Clin Interv Aging  2017,12,1313-1330","journal-title":"Clin Interv Aging"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2019.04.018","volume":"3","author":"Kokame G.T.","year":"2019","unstructured":"Kokame G.T.; deCarlo T.E.; Kaneko K.N.; Omizo J.N.; Lian R.; Anti-vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy. Ophthalmol Retina  2019,3(9),744-752","journal-title":"Ophthalmol Retina"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.3390\/ijms231911769","volume":"23","author":"Galindo-Camacho R.M.","year":"2022","unstructured":"Galindo-Camacho R.M.; Blanco-Llamero C.; da Ana R.; Fuertes M.A.; Se\u00f1or\u00e1ns F.J.; Silva A.M.; Garc\u00eda M.L.; Souto E.B.; Therapeutic approaches for age-related macular degeneration. Int J Mol Sci  2022,23(19),11769","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1248\/bpb.b16-00437","volume":"40","author":"Tanetsugu Y.","year":"2017","unstructured":"Tanetsugu Y.; Tagami T.; Terukina T.; Ogawa T.; Ohta M.; Ozeki T.; Development of a sustainable release system for a ranibizumab biosimilar using poly(lactic-co-glycolic acid) biodegradable polymer-based microparticles as a platform. Biol Pharm Bull  2017,40(2),145-150","journal-title":"Biol Pharm Bull"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1002\/jbm.a.35446","volume":"103","author":"Varshochian R.","year":"2015","unstructured":"Varshochian R.; Riazi-Esfahani M.; Jeddi-Tehrani M.; Mahmoudi A.R.; Aghazadeh S.; Mahbod M.; Movassat M.; Atyabi F.; Sabzevari A.; Dinarvand R.; Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A  2015,103(10),3148-3156","journal-title":"J Biomed Mater Res A"},{"key":"ref=15","first-page":"7","volume":"9","author":"Mynampati B.","year":"2020","unstructured":"Mynampati B.; Enghelberg M.; Chalam K.V.; Pazopanib selectively inhibits choroidal vascular endothelial cell proliferation and promotes apoptosis. Med Hypothesis Discov Innov Ophthalmol  2020,9(1),7-14","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.colsurfb.2017.07.038","volume":"159","author":"Mir M.","year":"2017","unstructured":"Mir M.; Ahmed N.; Rehman A.; Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Biointerfaces  2017,159,217-231","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"Makadia H.K.","year":"2011","unstructured":"Makadia H.K.; Siegel S.J.; Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers  2011,3(3),1377-1397","journal-title":"Polymers"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/10837450.2014.965326","volume":"21","author":"Hirani A.","year":"2016","unstructured":"Hirani A.; Grover A.; Lee Y.W.; Pathak Y.; Sutariya V.; Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration. Pharm Dev Technol  2016,21(1),61-67","journal-title":"Pharm Dev Technol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.3390\/ijms24054333","volume":"24","author":"Guo X.","year":"2023","unstructured":"Guo X.; Zuo X.; Zhou Z.; Gu Y.; Zheng H.; Wang X.; Wang G.; Xu C.; Wang F.; PLGA-based micro\/nanoparticles: An overview of their applications in respiratory diseases. Int J Mol Sci  2023,24(5),4333","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12249-023-02502-1","volume":"24","author":"Mahar R.","year":"2023","unstructured":"Mahar R.; Chakraborty A.; Nainwal N.; Bahuguna R.; Sajwan M.; Jakhmola V.; Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech  2023,24(1),39","journal-title":"AAPS PharmSciTech"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","volume":"28","author":"Su Y.","year":"2021","unstructured":"Su Y.; Zhang B.; Sun R.; Liu W.; Zhu Q.; Zhang X.; Wang R.; Chen C.; PLGA-based biodegradable microspheres in drug delivery: Recent advances in research and application. Drug Deliv  2021,28(1),1397-1418","journal-title":"Drug Deliv"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"109626","DOI":"10.1016\/j.exer.2023.109626","volume":"235","author":"Marquina S.","year":"2023","unstructured":"Marquina S.; Ozgul M.; Robertson-Brown K.; Kenney M.C.; A review on PLGA particles as a sustained drug-delivery system and its effect on the retina. Exp Eye Res  2023,235,109626","journal-title":"Exp Eye Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.biomaterials.2014.12.019","volume":"44","author":"Puntel A.","year":"2015","unstructured":"Puntel A.; Maeda A.; Golczak M.; Gao S.Q.; Yu G.; Palczewski K.; Lu Z.R.; Prolonged prevention of retinal degeneration with retinylamine loaded nanoparticles. Biomaterials  2015,44,103-110","journal-title":"Biomaterials"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.18433\/J3DP43","volume":"17","author":"Almeida H.","year":"2014","unstructured":"Almeida H.; Amaral M.H.; Lob\u00e3o P.; Silva A.C.; Loboa J.M.S.; Applications of polymeric and lipid nanoparticles in ophthalmic pharmaceutical formulations: present and future considerations. J Pharm Pharm Sci  2014,17(3),278-293","journal-title":"J Pharm Pharm Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1021\/acs.molpharmaceut.6b00335","volume":"13","author":"Elsaid N.","year":"2016","unstructured":"Elsaid N.; Jackson T.L.; Elsaid Z.; Alqathama A.; Somavarapu S.; PLGA microparticles entrapping chitosan-based nanoparticles for the ocular delivery of ranibizumab. Mol Pharm  2016,13(9),2923-2940","journal-title":"Mol Pharm"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/nnm-2016-0379","volume":"12","author":"Joseph R.R.","year":"2017","unstructured":"Joseph R.R.; Venkatraman S.S.; Drug delivery to the eye: What benefits do nanocarriers offer? Nanomedicine (Lond)  2017,12(6),683-702","journal-title":"Nanomedicine (Lond)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e1473","DOI":"10.1002\/wnan.1473","volume":"10","author":"Bisht R.","year":"2018","unstructured":"Bisht R.; Mandal A.; Jaiswal J.K.; Rupenthal I.D.; Nanocarrier mediated retinal drug delivery: Overcoming ocular barriers to treat posterior eye diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol  2018,10(2),e1473","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.3390\/pharmaceutics13122035","volume":"13","author":"Yang B.","year":"2021","unstructured":"Yang B.; Li G.; Liu J.; Li X.; Zhang S.; Sun F.; Liu W.; Nanotechnology for age-related macular degeneration. Pharmaceutics  2021,13(12),2035","journal-title":"Pharmaceutics"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.biopha.2018.08.092","volume":"107","author":"Zhang X.P.","year":"2018","unstructured":"Zhang X.P.; Sun J.G.; Yao J.; Shan K.; Liu B.H.; Yao M.D.; Ge H.M.; Jiang Q.; Zhao C.; Yan B.; Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy. Biomed Pharmacother  2018,107,1056-1063","journal-title":"Biomed Pharmacother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jcma.2015.07.008","volume":"78","author":"Lin T.C.","year":"2015","unstructured":"Lin T.C.; Hung K.H.; Peng C.H.; Liu J.H.; Woung L.C.; Tsai C.Y.; Chen S.J.; Chen Y.T.; Hsu C.C.; Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration. J Chin Med Assoc  2015,78(11),635-641","journal-title":"J Chin Med Assoc"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jphotobiol.2018.04.033","volume":"183","author":"Yan J.","year":"2018","unstructured":"Yan J.; Peng X.; Cai Y.; Cong W.; Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy. J Photochem Photobiol B  2018,183,133-136","journal-title":"J Photochem Photobiol B"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3390\/pharmaceutics13040560","volume":"13","author":"Chirio D.","year":"2021","unstructured":"Chirio D.; Peira E.; Sapino S.; Chindamo G.; Oliaro-Bosso S.; Adinolfi S.; Dianzani C.; Baratta F.; Gallarate M.; A new bevacizumab carrier for intravitreal administration: focus on stability. Pharmaceutics  2021,13(4),560","journal-title":"Pharmaceutics"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jconrel.2017.09.036","volume":"266","author":"Suda K.","year":"2017","unstructured":"Suda K.; Murakami T.; Gotoh N.; Fukuda R.; Hashida Y.; Hashida M.; Tsujikawa A.; Yoshimura N.; High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. J Control Release  2017,266,301-309","journal-title":"J Control Release"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2108360","DOI":"10.1002\/adma.202108360","volume":"34","author":"Zhao X.","year":"2022","unstructured":"Zhao X.; Seah I.; Xue K.; Wong W.; Tan Q.S.W.; Ma X.; Lin Q.; Lim J.Y.C.; Liu Z.; Parikh B.H.; Mehta K.N.; Lai J.W.; Yang B.; Tran K.C.; Barathi V.A.; Cheong K.H.; Hunziker W.; Su X.; Loh X.J.; Antiangiogenic nanomicelles for the topical delivery of aflibercept to treat retinal neovascular disease. Adv Mater  2022,34(25),2108360","journal-title":"Adv Mater"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.8b01319","volume":"16","author":"Qiu F.","year":"2019","unstructured":"Qiu F.; Meng T.; Chen Q.; Zhou K.; Shao Y.; Matlock G.; Ma X.; Wu W.; Du Y.; Wang X.; Deng G.; Ma J.; Xu Q.; Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration. Mol Pharm  2019,16(5),1958-1970","journal-title":"Mol Pharm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e04589","DOI":"10.1016\/j.heliyon.2020.e04589","volume":"6","author":"Laddha U.D.","year":"2020","unstructured":"Laddha U.D.; Kshirsagar S.J.; Formulation of PPAR-gamma agonist as surface modified PLGA nanoparticles for non-invasive treatment of diabetic retinopathy: in vitro and in vivo evidences. Heliyon  2020,6(8),e04589","journal-title":"Heliyon"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1208\/s12249-020-01836-4","volume":"21","author":"Bhatt P.","year":"2020","unstructured":"Bhatt P.; Fnu G.; Bhatia D.; Shahid A.; Sutariya V.; Nanodelivery of resveratrol-loaded PLGA nanoparticles for age-related macular degeneration. AAPS PharmSciTech  2020,21(8),291","journal-title":"AAPS PharmSciTech"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s11010-023-04865-2","volume":"479","author":"Sutariya V.","year":"2024","unstructured":"Sutariya V.; Bhatt P.; Saini A.; Miller A.; Badole S.L.; Tur J.; Gittinger M.; Kim J.W.; Manickam R.; Tipparaju S.M.; Development and testing of nanoparticles delivery for P7C3 small molecule using injury models. Mol Cell Biochem  2024,479(9),2429-2445","journal-title":"Mol Cell Biochem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ijpharm.2017.08.064","volume":"532","author":"Mart\u00ednez Rivas C.J.","year":"2017","unstructured":"Mart\u00ednez Rivas C.J.; Tarhini M.; Badri W.; Miladi K.; Greige-Gerges H.; Nazari Q.A.; Galindo Rodr\u00edguez S.A.; Rom\u00e1n R.\u00c1.; Fessi H.; Elaissari A.; Nanoprecipitation process: From encapsulation to drug delivery. Int J Pharm  2017,532(1),66-81","journal-title":"Int J Pharm"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"102474","DOI":"10.1016\/j.cis.2021.102474","volume":"294","author":"Yan X.","year":"2021","unstructured":"Yan X.; Bernard J.; Ganachaud F.; Nanoprecipitation as a simple and straightforward process to create complex polymeric colloidal morphologies. Adv Colloid Interface Sci  2021,294,102474","journal-title":"Adv Colloid Interface Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12896-023-00811-8","volume":"23","author":"Nouruzi E.","year":"2023","unstructured":"Nouruzi E.; Hosseini S.M.; Asghari B.; Mahjoub R.; Zare E.N.; Shahbazi M.A.; Kalhori F.; Arabestani M.R.; Effect of poly (lactic-co-glycolic acid) polymer nanoparticles loaded with vancomycin against Staphylococcus aureus biofilm. BMC Biotechnol  2023,23(1),39","journal-title":"BMC Biotechnol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/adt.2019.920","volume":"17","author":"Narvekar P.","year":"2019","unstructured":"Narvekar P.; Bhatt P.; Fnu G.; Sutariya V.; Axitinib-loaded poly (lactic-co-glycolic acid) nanoparticles for age-related macular degeneration: Formulation development and in vitro characterization. Assay Drug Dev Technol  2019,17(4),167-177","journal-title":"Assay Drug Dev Technol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jddst.2018.03.027","volume":"45","author":"Yewale C.","year":"2018","unstructured":"Yewale C.; Baradia D.; Patil S.; Bhatt P.; Amrutiya J.; Gandhi R.; Kore G.; Misra A.; Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. J Drug Deliv Sci Technol  2018,45,334-345","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"110951","DOI":"10.1039\/C6RA24058E","volume":"6","author":"Patil S.","year":"2016","unstructured":"Patil S.; Bhatt P.; Lalani R.; Amrutiya J.; Vhora I.; Kolte A.; Misra A.; Low molecular weight chitosan\u2013protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances  2016,6(112),110951-110963","journal-title":"RSC Advances"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1089\/adt.2022.004","volume":"20","author":"Sharma A.","year":"2022","unstructured":"Sharma A.; Streets J.; Bhatt P.; Patel P.; Sutariya V.; Varghese Gupta S.; Formulation and characterization of raloxifene nanostructured lipid carriers for permeability and uptake enhancement applications. Assay Drug Dev Technol  2022,20(4),164-174","journal-title":"Assay Drug Dev Technol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"122944","DOI":"10.1016\/j.ijpharm.2023.122944","volume":"639","author":"Wang R.","year":"2023","unstructured":"Wang R.; Zou L.; Yi Z.; Zhang Z.; Zhao M.; Shi S.; PLGA nanoparticles loaded with curcumin produced luminescence for cell bioimaging. Int J Pharm  2023,639,122944","journal-title":"Int J Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1089\/adt.2021.027","volume":"19","author":"Madan J.R.","year":"2021","unstructured":"Madan J.R.; Dere S.G.; Awasthi R.; Dua K.; Efavirenz loaded mixed polymeric micelles: formulation, optimization, and in vitro characterization. Assay Drug Dev Technol  2021,19(5),322-334","journal-title":"Assay Drug Dev Technol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/FTD.0000000000000121","volume":"37","author":"Escudero-Ortiz V.","year":"2015","unstructured":"Escudero-Ortiz V.; P\u00e9rez-Ruixo J.J.; Valenzuela B.; Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. Ther Drug Monit  2015,37(2),172-179","journal-title":"Ther Drug Monit"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.3390\/molecules25184243","volume":"25","author":"Sharma N.","year":"2020","unstructured":"Sharma N.; Kumari R.M.; Gupta N.; Syed A.; Bahkali A.H.; Nimesh S.; Poly-(lactic-co-glycolic) acid nanoparticles for synergistic delivery of epirubicin and paclitaxel to human lung cancer cells. Molecules  2020,25(18),4243","journal-title":"Molecules"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijpharm.2014.12.035","volume":"479","author":"Alibolandi M.","year":"2015","unstructured":"Alibolandi M.; Ramezani M.; Sadeghi F.; Abnous K.; Hadizadeh F.; Epithelial cell adhesion molecule aptamer conjugated PEG\u2013PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro. Int J Pharm  2015,479(1),241-251","journal-title":"Int J Pharm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"935","DOI":"10.31557\/APJCP.2020.21.4.935","volume":"21","author":"Muhamad N.","year":"2020","unstructured":"Muhamad N.; Plengsuriyakarn T.; Chittasupho C.; Na-Bangchang K.; The potential of atractylodin-loaded PLGA nanoparticles as chemotherapeutic for cholangiocarcinoma. Asian Pac J Cancer Prev  2020,21(4),935-941","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3109\/10717544.2014.898348","volume":"22","author":"Bhatt P.","year":"2015","unstructured":"Bhatt P.; Khatri N.; Kumar M.; Baradia D.; Misra A.; Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: An effectual groundwork for colorectal cancer. Drug Deliv  2015,22(6),849-861","journal-title":"Drug Deliv"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.3390\/polym14204444","volume":"14","author":"Tahir A.","year":"2022","unstructured":"Tahir A.; Plengsuriyakarn T.; Chittasupho C.; Na-Bangchang K.; Potential of alpha-mangostin-loaded plga nanoparticles for cholangiocarcinoma treatment. Polymers  2022,14(20),4444","journal-title":"Polymers"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"117943","DOI":"10.1016\/j.lfs.2020.117943","volume":"256","author":"Madani F.","year":"2020","unstructured":"Madani F.; Esnaashari S.S.; Bergonzi M.C.; Webster T.J.; Younes H.M.; Khosravani M.; Adabi M.; Paclitaxel\/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation. Life Sci  2020,256,117943","journal-title":"Life Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ijbiomac.2021.09.069","volume":"191","author":"Suri R.","year":"2021","unstructured":"Suri R.; Neupane Y.R.; Mehra N.; Nematullah M.; Khan F.; Alam O.; Iqubal A.; Jain G.K.; Kohli K.; Sirolimus loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential treatment of age-related macular degeneration. Int J Biol Macromol  2021,191,548-559","journal-title":"Int J Biol Macromol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.2147\/IJN.S269340","volume":"15","author":"Ibrahim W.N.","year":"2020","unstructured":"Ibrahim W.N.; Muizzuddin Bin Mohd Rosli L.; Doolaanea A.A.; Formulation, cellular uptake and cytotoxicity of thymoquinone-loaded PLGA nanoparticles in malignant melanoma cancer cells. Int J Nanomedicine  2020,15,8059-8074","journal-title":"Int J Nanomedicine"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/03639045.2023.2185463","volume":"49","author":"Reddy G.A.","year":"2023","unstructured":"Reddy G.A.; Handa M.; Garabadu D.; Kumar R.; Kushawaha P.K.; Shukla R.; Transferrin decorated PLGA encumbered moxifloxacin nanoparticles and in vitro cellular studies. Drug Dev Ind Pharm  2023,49(1),129-138","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1089\/adt.2021.003","volume":"19","author":"Shahid A.","year":"2021","unstructured":"Shahid A.; Bhatt P.; Miller A.; Sutariya V.; Honokiol-loaded methoxy poly (ethylene glycol) polycaprolactone micelles for the treatment of age-related macular degeneration. Assay Drug Dev Technol  2021,19(6),350-360","journal-title":"Assay Drug Dev Technol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/biomedicines6030092","volume":"6","author":"Kelly S.J.","year":"2018","unstructured":"Kelly S.J.; Hirani A.; Shahidadpury V.; Solanki A.; Halasz K.; Varghese Gupta S.; Madow B.; Sutariya V.; Aflibercept nanoformulation inhibits VEGF expression in ocular in vitro model: A preliminary report. Biomedicines  2018,6(3),92","journal-title":"Biomedicines"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/02713683.2014.935440","volume":"40","author":"Kozlowski M.R.","year":"2015","unstructured":"Kozlowski M.R.; The ARPE-19 cell line: Mortality status and utility in macular degeneration research. Curr Eye Res  2015,40(5),501-509","journal-title":"Curr Eye Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1242\/dmm.017236","volume":"8","author":"Forest D.L.","year":"2015","unstructured":"Forest D.L.; Johnson L.V.; Clegg D.O.; Cellular models and therapies for age-related macular degeneration. Dis Model Mech  2015,8(5),421-427","journal-title":"Dis Model Mech"},{"key":"ref=62","first-page":"628","volume":"55","author":"Alrashed F.","year":"2014","unstructured":"Alrashed F.; Bennett A.; Kerr I.; Foss A.; Use of ARPE-19 cell line as an in-vitro model for age related macular degeneration. Invest Ophthalmol Vis Sci  2014,55(13),628","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"109170","DOI":"10.1016\/j.exer.2022.109170","volume":"222","author":"Bharti K.","year":"2022","unstructured":"Bharti K.; den Hollander A.I.; Lakkaraju A.; Sinha D.; Williams D.S.; Finnemann S.C.; Bowes-Rickman C.; Malek G.; D\u2019Amore P.A.; Cell culture models to study retinal pigment epithelium-related pathogenesis in age-related macular degeneration. Exp Eye Res  2022,222,109170","journal-title":"Exp Eye Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1421959","DOI":"10.3389\/fmolb.2024.1421959","volume":"11","author":"Baig M.S.","year":"2024","unstructured":"Baig M.S.; Karade S.K.; Ahmad A.; Khan M.A.; Haque A.; Webster T.J.; Faiyazuddin M.; Al-Qahtani N.H.; Lipid-based nanoparticles: Innovations in ocular drug delivery. Front Mol Biosci  2024,11,1421959","journal-title":"Front Mol Biosci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"15593258231152117","DOI":"10.1177\/15593258231152117","volume":"21","author":"Bukhari A.","year":"2023","unstructured":"Bukhari A.; Fatima Z.; Atta M.; Nazir A.; Alshawwa S.Z.; Alotaibi H.F.; Iqbal M.; Poly lactic-co-glycolic acid nano-carriers for encapsulation and controlled release of hydrophobic drug to enhance the bioavailability and antimicrobial properties. Dose Response  2023,21(1),15593258231152117","journal-title":"Dose Response"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"107711","DOI":"10.1016\/j.exer.2019.107711","volume":"186","author":"Huang X.","year":"2019","unstructured":"Huang X.; Chau Y.; Investigating impacts of surface charge on intraocular distribution of intravitreal lipid nanoparticles. Exp Eye Res  2019,186,107711","journal-title":"Exp Eye Res"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2204206","DOI":"10.1080\/10717544.2023.2204206","volume":"30","author":"Jiang H.","year":"2023","unstructured":"Jiang H.; Xu Z.; Hyaluronic acid-based nanoparticles to deliver drugs to the ocular posterior segment. Drug Deliv  2023,30(1),2204206","journal-title":"Drug Deliv"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/17425247.2023.2223941","volume":"20","author":"Narmani A.","year":"2023","unstructured":"Narmani A.; Jahedi R.; Bakhshian-Dehkordi E.; Ganji S.; Nemati M.; Ghahramani-Asl R.; Moloudi K.; Hosseini S.M.; Bagheri H.; Kesharwani P.; Khani A.; Farhood B.; Sahebkar A.; Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy. Expert Opin Drug Deliv  2023,20(7),937-954","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/21691401.2016.1243545","volume":"45","author":"Pandit J.","year":"2017","unstructured":"Pandit J.; Sultana Y.; Aqil M.; Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: Optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomed Biotechnol  2017,45(7),1397-1407","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2147\/IJN.S195048","volume":"14","author":"Anwer K.","year":"2019","unstructured":"Anwer K.; Mohammad M.; Ezzeldin E.; Fatima F.; Alalaiwe A.; Iqbal M.; Preparation of sustained release apremilast-loaded PLGA nanoparticles: In vitro characterization and in vivo pharmacokinetic study in rats. Int J Nanomedicine  2019,14,1587-1595","journal-title":"Int J Nanomedicine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.3390\/pharmaceutics14122728","volume":"14","author":"Alsaab H.O.","year":"2022","unstructured":"Alsaab H.O.; Alharbi F.D.; Alhibs A.S.; Alanazi N.B.; Alshehri B.Y.; Saleh M.A.; Alshehri F.S.; Algarni M.A.; Almugaiteeb T.; Uddin M.N.; Alzhrani R.M.; PLGA-Based nanomedicine: History of advancement and development in clinical applications of multiple diseases. Pharmaceutics  2022,14(12),2728","journal-title":"Pharmaceutics"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.pharma.2021.11.009","volume":"80","author":"Chavan Y.R.","year":"2022","unstructured":"Chavan Y.R.; Tambe S.M.; Jain D.D.; Khairnar S.V.; Amin P.D.; Redefining the importance of polylactide-co-glycolide acid (PLGA) in drug delivery. Ann Pharm Fr  2022,80(5),603-616","journal-title":"Ann Pharm Fr"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/ph16030454","volume":"16","author":"Lu Y.","year":"2023","unstructured":"Lu Y.; Cheng D.; Niu B.; Wang X.; Wu X.; Wang A.; Properties of poly (lactic-co-glycolic acid) and progress of poly (lactic-co-glycolic acid)-based biodegradable materials in biomedical research. Pharmaceuticals  2023,16(3),454","journal-title":"Pharmaceuticals"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.actbio.2018.04.006","volume":"73","author":"Swider E.","year":"2018","unstructured":"Swider E.; Koshkina O.; Tel J.; Cruz L.J.; de Vries I.J.M.; Srinivas M.; Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater  2018,73,38-51","journal-title":"Acta Biomater"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"122484","DOI":"10.1016\/j.ijpharm.2022.122484","volume":"631","author":"Rahmani F.","year":"2023","unstructured":"Rahmani F.; Atabaki R.; Behrouzi S.; Mohamadpour F.; Kamali H.; The recent advancement in the PLGA-based thermo-sensitive hydrogel for smart drug delivery. Int J Pharm  2023,631,122484","journal-title":"Int J Pharm"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/pharmaceutics15020495","volume":"15","author":"Noorain L.","year":"2023","unstructured":"Noorain L.; Nguyen V.; Kim H.W.; Nguyen L.T.B.; A machine learning approach for PLGA nanoparticles in antiviral drug delivery. Pharmaceutics  2023,15(2),495","journal-title":"Pharmaceutics"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41598-023-27500-y","volume":"13","author":"Watcharadulyarat N.","year":"2023","unstructured":"Watcharadulyarat N.; Rattanatayarom M.; Ruangsawasdi N.; Patikarnmonthon N.; PEG\u2013PLGA nanoparticles for encapsulating ciprofloxacin. Sci Rep  2023,13(1),266","journal-title":"Sci Rep"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"111060","DOI":"10.1039\/C6RA23620K","volume":"6","author":"Espa\u00f1ol L.","year":"2016","unstructured":"Espa\u00f1ol L.; Larrea A.; Andreu V.; Mendoza G.; Arruebo M.; Sebastian V.; Aurora-Prado M.S.; Kedor-Hackmann E.R.M.; Santoro M.I.R.M.; Santamaria J.; Dual encapsulation of hydrophobic and hydrophilic drugs in PLGA nanoparticles by a single-step method: Drug delivery and cytotoxicity assays. RSC Advances  2016,6(112),111060-111069","journal-title":"RSC Advances"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"897","DOI":"10.35333\/jrp.2019.37","volume":"23","author":"Ozturk A.A.","year":"2019","unstructured":"Ozturk A.A.; Kirimlioglu G.Y.; Preparation and in vitro characterization of lamivudine loaded nanoparticles prepared by acid and\/or ester terminated PLGA for effective oral anti-retroviral therapy. J Res Pharm  2019,23(5),897-913","journal-title":"J Res Pharm"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"41","DOI":"10.18502\/jovr.v19i1.15436","volume":"19","author":"Chaharband F.","year":"2024","unstructured":"Chaharband F.; Varshochian R.; Dinarvand R.; Sabbaghi H.; Rezaei Kanavi M.; Daftarian N.; Nourinia R.; Polymeric propranolol nanoparticles for intraocular delivery: formulation, characterization, and vitreous pharmacokinetics. J Ophthalmic Vis Res  2024,19(1),41-50","journal-title":"J Ophthalmic Vis Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.msec.2019.03.060","volume":"100","author":"Ahmad I.","year":"2019","unstructured":"Ahmad I.; Pandit J.; Sultana Y.; Mishra A.K.; Hazari P.P.; Aqil M.; Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. Mater Sci Eng C  2019,100,959-970","journal-title":"Mater Sci Eng C"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/10717544.2022.2048134","volume":"29","author":"Luo Q.","year":"2022","unstructured":"Luo Q.; Yang J.; Xu H.; Shi J.; Liang Z.; Zhang R.; Lu P.; Pu G.; Zhao N.; Zhang J.; Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: Development, in-vitro and in vivo study. Drug Deliv  2022,29(1),837-855","journal-title":"Drug Deliv"},{"key":"ref=83","first-page":"484","volume":"119","author":"Moraru A.D.","year":"2015","unstructured":"Moraru A.D.; Costuleanu M.; Costin D.; Peptu C.; Popa M.; Chiseli\u0163\u0103 D.; Intraocular biodistribution of intravitreal injected fluorescent dexamethasone-chitosan nanoparticles in rabbit eyes. Rev Med Chir Soc Med Nat Iasi  2015,119(2),484-490","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"123336","DOI":"10.1016\/j.ijpharm.2023.123336","volume":"645","author":"Erdal E.","year":"2023","unstructured":"Erdal E.; Bakici C.; Arslan A.; Batur B.; Yaman M.E.; Al\u00e7\u0131\u011f\u0131r M.E.; Akyol M.; Ekim O.; Salih B.; U\u011furlu N.; Ocular pharmacokinetics and toxicity of nanoparticular acetazolamide: In vivo distribution and safety of PHBV-ACZ nanoparticle. Int J Pharm  2023,645,123336","journal-title":"Int J Pharm"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018385478251124140833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/249135\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018385478251124140833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:40:56Z","timestamp":1790145656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/249135\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":84,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018385478251124140833","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}